Rilonacept
| Clinical data | |
|---|---|
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Rilonacept (marketed under the tradename Arcalyst), is a dimeric fusion protein for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It was given an "Orphan Drug" status by the United States Food and Drug Administration.
It was approved by the FDA on February 2008.[1]
References
External links
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Monoclonal antibody stubs
- Monoclonal antibodies
- Engineered proteins